Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Weiwen Lu, Zhongbo Zhou, Neng Jiang & Jing Han. (2023) An updated patent review of GLP-1 receptor agonists (2020-present). Expert Opinion on Therapeutic Patents 33:9, pages 597-612.
Read now
Read now
Articles from other publishers (23)
Xiang Zhang, Suki Ha, Harry Cheuk-Hay Lau & Jun Yu. (2023) Excess body weight: Novel insights into its roles in obesity comorbidities. Seminars in Cancer Biology 92, pages 16-27.
Crossref
Crossref
Ainhoa Gómez Lumbreras, Malinda S. Tan, Lorenzo Villa-Zapata, Sabrina Ilham, Jacob C. Earl & Daniel C. Malone. (2023) Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective. Nutrition, Metabolism and Cardiovascular Diseases 33:6, pages 1268-1276.
Crossref
Crossref
Yao Zhihong, Wang Chen, Zhu Qianqian, Sun Lidan, Zhou Qiang, Han Jing, Wang Wenxi & Ruchika Bhawal. (2023) Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity. Peptides 162, pages 170955.
Crossref
Crossref
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, Caline Rhayem, Raya Tcheroyan & Christos S. Mantzoros. (2023) Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine 58, pages 101882.
Crossref
Crossref
Nayyar Iqbal, Philip Ambery, Jennifer Logue, Ashwini Mallappa & C David Sjöström. (2023) Perspectives In Weight Control In Diabetes – Sglt2 Inhibitors And Glp-1–Glucagon Dual Agonism. Diabetes Research and Clinical Practice, pages 110669.
Crossref
Crossref
Xiaolong Zhang, Yuchen Cai, Zhihong Yao, Heng Chi, Yan Li, Jingjing Shi, Zhongbo Zhou & Lidan Sun. (2023) Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists. Peptides 161, pages 170948.
Crossref
Crossref
Simon-Okomo Aloo, Fred Kwame Ofosu, Nam-Hyeon Kim, Sheila M. Kilonzi & Deog-Hwan Oh. (2023) Insights on Dietary Polyphenols as Agents against Metabolic Disorders: Obesity as a Target Disease. Antioxidants 12:2, pages 416.
Crossref
Crossref
Naresh M. Venneti, Ganesh Samala, Rana M. I. Morsy, Lawrence G. Mendoza, Albert Isidro-Llobet, Janine K. Tom, Subha Mukherjee, Michael E. Kopach & Jennifer L. Stockdill. (2023) Phosphine-Dependent Photoinitiation of Alkyl Thiols under Near-UV Light Facilitates User-Friendly Peptide Desulfurization. Journal of the American Chemical Society 145:2, pages 1053-1061.
Crossref
Crossref
Antonella M. D’Ascanio, Jamie A. Mullally & William H. Frishman. (2023) Cagrilintide. Cardiology in Review Publish Ahead of Print.
Crossref
Crossref
Elena Jiménez-Martí, Gema Hurtado-Genovés, María Aguilar-Ballester, Sergio Martínez-Hervás & Herminia González-Navarro. (2022) Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists. Nutrients 14:18, pages 3775.
Crossref
Crossref
Yunfeng Yu, Gang Hu, Shuang Yin, Xinyu Yang, Manli Zhou & Weixiong Jian. (2022) Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin & Jinbo Yang. (2022) Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Nicholas W. S. Chew, Cheng Han Ng, Emily Truong, Mazen Noureddin & Kris V. Kowdley. (2022) Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. Seminars in Liver Disease 42:03, pages 379-400.
Crossref
Crossref
Naazneen Arastu, Olivia Cummins, Wanda Uribe & Eric C. Nemec. (2022) Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis. International Journal of Clinical Pharmacy 44:4, pages 852-859.
Crossref
Crossref
Harold E. Bays, Angela Fitch, Sandra Christensen, Karli Burridge & Justin Tondt. (2022) Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2, pages 100018.
Crossref
Crossref
Mojca Jensterle, Manfredi Rizzo, Martin Haluzík & Andrej Janež. (2022) Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Advances in Therapy 39:6, pages 2452-2467.
Crossref
Crossref
Stergios A. Polyzos, Dimitrios G. Goulis, Olga Giouleme, Georgios S. Germanidis & Antonis Goulas. (2022) Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. Current Obesity Reports 11:3, pages 166-179.
Crossref
Crossref
David S. Mathiesen, Jonatan I. Bagger & Filip K. Knop. (2022) Long-acting amylin analogues for the management of obesity. Current Opinion in Endocrinology, Diabetes & Obesity 29:2, pages 183-190.
Crossref
Crossref
Bertrand Cariou. (2022) The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. Diabetes, Obesity and Metabolism 24:S2, pages 15-27.
Crossref
Crossref
Daniel B. Andersen & Jens J. Holst. (2022) Peptides in the regulation of glucagon secretion. Peptides 148, pages 170683.
Crossref
Crossref
Renata Spezani & Carlos Alberto Mandarim-de-Lacerda. (2022) The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon. Life Sciences 288, pages 120188.
Crossref
Crossref
Mojca Jensterle & Andrej Janež. (2021) Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity. Hormone Research in Paediatrics.
Crossref
Crossref
André J. Scheen. (2021) Médicaments anti-obésité : leçons des échecs pour l’avenir. Médecine des Maladies Métaboliques 15:8, pages 734-743.
Crossref
Crossref